 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gagnants
Le titre Etao International Co (NASDAQ:ETAO) a mont vendredi de 25,61% 3,58 dollars lors de la session pre-market.
Le titre Protara Therapeutics (NASDAQ:TARA) a augment de 21,39% 4,88...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 05/04/2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Protara Therapeutics announces $45M private placement financing

Titoli in rialzo
Le azioni di Protara Therapeutics (NASDAQ:TARA) hanno fatto segnare +29,35% a 5,20 dollari durante la sessione pre-market di venerd .
Il titolo Etao International Co (NASDAQ:ETAO) ha...

12 titoli sanitari in movimento, pre-market del 05/04/2024

Acciones al alza
Etao International Co (NASDAQ:ETAO) experimentaron un repunte del 25,61% para establecerse en los 3,58 d lares durante la sesi n del pre-market del viernes.
Protara Therapeutics...

12 acciones de salud en movimiento durante la preapertura del 05/04/2024

Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq...

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline...

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive/Experienced patients in ongoing NMIBC programTARA-002 demonstrated a complete response rate of 63% at three...

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with...

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Protara Therapeutics (TARA Research Report), with a price target of...

Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Volume (M)	207,962.00
52-Wk High	$5.24
52-Wk Low	$1.04

TARA Protara Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals